Insulin Pump Market: Large Population of Diabetes patients, rising ageing population, chronic nature of the disease are key drivers for Global Insulin Pump Company Market. Insulin Pump Company Market was worth of around USD 4691.34 Million in 2017 and it is estimated to reach about USD 8740.87 Million by the end of 2024 with significant CAGR of approximately 9.25%.
An insulin pump is a small, battery-operated, portable device about the size of a cellphone or a pager. It is worn externally either in the patient’s pocket or on a special belt, or it can be concealed under the clothing.
An insulin pump attempts to mimic the function of a normal pancreas that secretes insulin. Insulin pumps help diabetes patients control their blood sugar levels more efficiently and more easily. Diabetics generally prefer insulin pumps to daily injections. It is often prescribed to type 1 diabetes patients, and, in some cases, it may be prescribed to type 2 diabetes patients depending on the case.
The patient must be mentally stable and has a strong sense of responsibility. The patient must commit to self-measuring glucose levels. Insulin doses must be determined based on blood glucose levels, the amount carbohydrates in meals, and daily activities. The patient must be capable of calculating carbohydrates.
Insulin pumps are programmed to automatically deliver certain amounts of fast-acting insulin that is stored in the pump’s reservoir. Insulin is delivered to the body through a tube attached to a small plastic needle, which is inserted under the skin. This allows the skin to absorb insulin gradually. Insulin doses can be easily adjusted at any time.
It improves the patient’s quality of life and makes it easier for them to live with the disease. Fewer injections and needles. Tighter control over blood sugar levels (it reduces the risk of low blood sugar and improves average blood sugar levels). Easier and more efficient insulin delivery (with the press of a button). Insulin pumps allow patients more flexibility with their meal choices, mealtimes, and daily activities.
Medtronic began its operations in India in the year 1979. With over 1100 employees, India Medtronic Pvt. Ltd. is a wholly-owned subsidiary of Medtronic Plc. It is headquartered at Solitaire Corporate Park in Mumbai and has its offices at Ahmedabad, Bangalore, Chennai, Cochin, Dhaka, Gurgaon, Hyderabad, Kolkata, New Delhi, Pune and Vadodara and Colombo.
Our businesses primarily fall into four groups: the Cardiac and Vascular Group (CVG), the Restorative Therapies Group (RTG), the Diabetes Group and the Minimally Invasive Therapies Group (MITG). The Cardiac and Vascular Group encompasses Cardiac Rhythm and Heart Failure (CRHF), Coronary, Structural Heart and Arterial and Peripheral Vascular businesses; the Restorative Therapies Group includes Spine and Biologics, Surgical Technologies, Neuromodulation and Neurovascular businesses; the Diabetes Group offers Insulin Pump Therapy and Continuous Glucose Monitoring Systems (CGMS) and the Minimally Invasive Therapies group comprises of Early Technologies, Advanced Surgical Technologies and General Surgical Products, and Medical Supplies, Respiratory and Monitoring Solutions, and Venous Solutions.
Tandem Diabetes Care
In Tandem” means together, and we strive to embody that in every aspect of our business. We believe that working in tandem, not in isolation, is the best way to continually exceed expectations.
In the development of our first product, the t:slim® Insulin Pump, we conducted thousands of interviews with people living with diabetes and their healthcare providers, and have continued using this design approach in the development of all of our products. We believe that by listening to the needs of both patients and providers, we have a better chance of delivering products that will help improve their lives.
At Tandem, we are not a diabetes division, we are a diabetes company. Our whole reason for being is to make the lives of people with diabetes better and better, through relentless innovation and revolutionary customer experience.
MicroPort® was founded in 1998 in a small office in ZJ Hi-Tech Park in Shanghai China, where a group of dedicated individuals joined together by the common belief that advancements in medical technology could transform patients' lives around the globe. Over the last two decades, MicroPort® has taken important steps towards fulfilling its mission of providing access to the best means of prolonging and reshaping livesa.
Today, one in five Americans experience a diagnosable mental illness, yet 84% aren’t getting the care they need. Unfortunately, traditional mental health solutions were not built to acknowledge the unique needs of each person. This results in a terrible experience, as patients must test multiple treatment and provider options to find the right fit.
At Spring Health, we believe that mental healthcare is not ‘one size fits all.’ By applying the same scientific principles behind precision medicine to mental healthcare, we can accurately predict the right treatment to the right person at the right time, and ultimately accelerate recovery. We call this Precision Mental Healthcare.
Since 1990, Debiotech's aim has been to conceive and develop highly innovative and cost effective Medical Devices, improving the therapeutical outcome and the Quality of Life for the highest possible number of patients. The specificity of the company is to devote itself to the definition, design and development of devices, leaving to licensed partners or acquirers the responsibility of marketing and sales of the products.
With over 20 different medical product developments, over 40 license agreements, numerous prestigious awards and more than 500 granted national patents, Debiotech is ranked as one of the most innovative company for Medical Devices in Switzerland.
Debiotech performs R&D based on breakthrough discoveries on Artificial Organs, Drug Delivery Systems, Diagnostics, Medical Devices, Micro-, Nano- and Information technology in an independent entrepreneurial environment which permits rapid decision making.
Sanofi, Synthélabo, Hoechst, Rhône-Poulenc Rorer led to the creation of Sanofi. These companies have accumulated over a century of experience in health, with a core concern of innovation to meet the evolution of society and the needs of patients.
Today, the Sanofi Company and its 100,000 employees are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
In 1888, physician and drug store proprietor Dr. Wallace C. Abbott began producing accurate, scientifically formulated medications with the goal of providing more effective therapies to patients and the physicians providing their care.
Under the pioneering leadership of Dr. Abbott, our company was among the founders of the scientific practice of pharmacy, expanding its business to meet rising global health needs by championing new areas of medical research. By continually entering new areas—both scientific and geographic—we've established a now long-standing tradition of helping people live healthier lives around the world.
Insulin Pump Company Market Segmentation -
By Product Type
By End User